anti-EGFR/c-Met bispecific antibody CKD-702

A tetravalent, bispecific antibody composed of a single-chain variable fragment (scFv) targeting epidermal growth factor receptor (EGFR) fused to the c-terminus of an immunoglobulin G1 (IgG1) antibody targeting hepatocyte growth factor receptor (HGFR; c-Met), with potential antineoplastic activity. Upon administration, anti-EGFR/c-Met bispecific antibody CKD-702 simultaneously targets and binds to the extracellular domains of wild-type or certain mutant forms of both EGFR and c-Met expressed on cancer cells, thereby preventing receptor phosphorylation. This prevents the activation of both EGFR- and c-Met-mediated signaling pathways. In addition, binding results in receptor degradation, which further inhibits EGFR- and c-Met-mediated signaling, thereby inhibiting tumor cell proliferation. EGFR and c-Met, both upregulated or mutated in a variety of tumor cell types, play key roles in tumor cell proliferation.